1. |
Zhong JH, Torzilli G, Xing H, et al. Controversies and evidence of hepatic resection for hepatocellular carcinoma. BBA Clin, 2016, 6: 125-130.
|
2. |
Gavriilidis P, Askari A, Azoulay D. Survival following redo hepatectomy vs radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford), 2017, 19(1): 3-9.
|
3. |
Tanaka K, Shimada H, Matsuo K, et al. Regeneration after two-stage hepatectomy vs. repeat resection for colorectal metastasis recurrence. J Gastrointest Surg, 2007, 11(9): 1154-1161.
|
4. |
Loss M, Jung EM, Scherer MN, et al. Surgical treatment of liver metastases. Chirurg, 2010, 81(6): 533-541.
|
5. |
Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg, 2012, 255(3): 405-414.
|
6. |
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 1982, 5(6): 649-655.
|
7. |
Sotiropoulos GC, Lang H, Frilling A, et al. Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature. Hepatogastroenterology, 2006, 53(69): 322-329.
|
8. |
Suciu BA, Gurzu S, Marginean L, et al. Significant Shrinkage of Multifocal Liver Metastases and Long-Term Survival in a Patient With Rectal Cancer, After Trans-Arterial Chemoembolization (TACE): A Case Report. Medicine (Baltimore), 2015, 94(42): e1848.
|
9. |
Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis, 2016, 48(6): 571-577.
|
10. |
Lu W, Li YH, Yu ZJ, et al. A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma. Hepatogastroenterology, 2007, 54(77): 1499-1502.
|
11. |
Kwak HW, Park JW, Nam BH, et al. Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol, 2014, 29(4): 820-829.
|
12. |
D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol, 2006, 44(1): 217-231.
|
13. |
Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002, 35(5): 1164-1171.
|
14. |
Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002, 359(9319): 1734-1739.
|
15. |
王翔翔, 余华, 熊杰, 等. 肝动脉化疗栓塞对原发性肝癌患者术后生存及复发的影响. 中国普外基础与临床杂志, 2012, 19(11): 1204-1207.
|
16. |
Bae SI, Yeon JE, Lee JM, et al. A case of necrotizing pancreatitis subsequent to transcatheter arterial chemoembolization in a patient with hepatocellular carcinoma. Clin Mol Hepatol, 2012, 18(3): 321-325.
|
17. |
Miyayama S, Yamashiro M, Okuda M, et al. Main bile duct stricture occurring after transcatheter arterial chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol, 2010, 33(6): 1168-1179.
|
18. |
Chu HJ, Lee CW, Yeh SJ, et al. Cerebral Lipiodol Embolism in Hepatocellular Carcinoma Patients Treated with Transarterial Embolization/Chemoembolization. PLoS One, 2015, 10(6): e0129367.
|
19. |
Toro A, Bertino G, Arcerito MC, et al. A lethal complication after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. Case Rep Surg, 2015, 2015: 873601.
|
20. |
Jia Z, Tian F, Jiang G. Ruptured hepatic carcinoma after transcatheter arterial chemoembolization. Curr Ther Res Clin Exp, 2013, 74: 41-43.
|
21. |
Edmondson MJ, Sodergren MH, Pucher PH, et al. Variations and adaptations of associated liver partition and portal vein ligation for staged hepatectomy (ALPPS): Many routes to the summit. Surgery, 2016, 159(4): 1058-1072.
|
22. |
Lam VW, Laurence JM, Johnston E, et al. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford), 2013, 15(7): 483-491.
|
23. |
Schadde E, Schnitzbauer AA, Tschuor C, et al. Systematic review and meta-analysis of feasibility, safety, and efficacy of a novel procedure: associating liver partition and portal vein ligation for staged hepatectomy. Ann Surg Oncol, 2015, 22(9): 3109-3120.
|
24. |
Truant S, Oberlin O, Sergent G, et al. Remnant liver volume to body weight ratio > or =0.5%: A new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver. J Am Coll Surg, 2007, 204(1): 22-33.
|
25. |
Tanaka K. Modified ALPPS procedures: more safety through less invasive surgery. Langenbecks Arch Surg, 2017, 402(4): 563-574.
|